NCT00154349

Efficacy Study of Imatinib Mesylate to Treat Philadelphia-Positive Acute Lymphocytic Leukemia

Phase II Study of Imatinib Mesylate for Philadelphia-Positive Acute Lymphocytic Leukemia

• Status: Completed
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 8 (actual)
• Sponsor: Novartis Pharmaceuticals · Industry
• Sex: All
• Age: 15 Years
• Healthy volunteers: Not accepted

Summary

The objective of this study is to determine the efficacy and safety of imatinib mesylate in patients diagnosed as having Philadelphia chromosome positive acute lymphocytic leukemia (ALL).

Conditions

• Philadelphia Chromosome Positive Acute Lymphocytic Leukemia

Interventions

Type	Name	Description
DRUG	Imatinib Mesylate

Timeline

• Start date: 2003-10-01
• Primary completion: 2007-02-01
• Completion: 2007-02-01
• First posted: 2005-09-12
• Last updated: 2017-02-23